Propanc Biopharma, Inc.: Form 10-Q for the period ended Sep 30, 2022
Filed with the SEC on Nov 14, 2022 and accepted by EDGAR at Nov 14, 2022, 16:34 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2022-07-01 to 2022-09-30 | $101.3k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2022-07-01 to 2022-09-30 | −$572.8k | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2022-07-01 to 2022-09-30 | $162.8k | us-gaap:InterestExpense |
| Net income | 3 months2022-07-01 to 2022-09-30 | −$617.3k | us-gaap:NetIncomeLoss |
| Basic EPS | 3 months2022-07-01 to 2022-09-30 | $0.00 | us-gaap:EarningsPerShareBasic |
| Operating cash flow | 3 months2022-07-01 to 2022-09-30 | −$509.3k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2022-09-30 | $19.4k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-09-30 | $37.9k | us-gaap:AssetsCurrent |
| Total assets | At period end2022-09-30 | $94.3k | us-gaap:Assets |
| Current liabilities | At period end2022-09-30 | $2.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2022-09-30 | $2.9m | us-gaap:Liabilities |
| Long-term debt | At period end2022-09-30 | $913.6k | us-gaap:LongTermDebt |
| Shareholders' equity | At period end2022-09-30 | −$2.8m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001493152-22-032116. Last ingested by Listed: Oct 29, 2026, 17:01 ET. Listed shows no prices and gives no investment advice.